KLK3 and Familial prostate cancer: In another retrospective analysis of 635 patients, prostate cancer–specific and overall survival were significantly improved in patients who received SRT within 2 years of biochemical recurrence among men with a PSA doubling time of less than 6 months, independent of other prognostic features such as pathological stage or Gleason score [11].